These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 29090344)

  • 1. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Nassereddine S; Lap CJ; Haroun F; Tabbara I
    Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enasidenib and ivosidenib in AML.
    Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
    Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
    Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH2 inhibition in AML: Finally progress?
    Stein EM
    Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
    Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
    Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enasidenib in mutant
    Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
    Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.
    Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK
    Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular remission and response patterns in patients with mutant-
    Stein EM; DiNardo CD; Fathi AT; Pollyea DA; Stone RM; Altman JK; Roboz GJ; Patel MR; Collins R; Flinn IW; Sekeres MA; Stein AS; Kantarjian HM; Levine RL; Vyas P; MacBeth KJ; Tosolini A; VanOostendorp J; Xu Q; Gupta I; Lila T; Risueno A; Yen KE; Wu B; Attar EC; Tallman MS; de Botton S
    Blood; 2019 Feb; 133(7):676-687. PubMed ID: 30510081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of IDH mutations in acute myeloid leukemia.
    Montalban-Bravo G; DiNardo CD
    Future Oncol; 2018 Apr; 14(10):979-993. PubMed ID: 29543066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
    Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
    Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enasidenib.
    Krämer A; Bochtler T
    Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the
    Amaya ML; Pollyea DA
    Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
    Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S;
    JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.
    Becker JS; Fathi AT
    Curr Cancer Drug Targets; 2020; 20(7):490-500. PubMed ID: 32329690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
    Quek L; David MD; Kennedy A; Metzner M; Amatangelo M; Shih A; Stoilova B; Quivoron C; Heiblig M; Willekens C; Saada V; Alsafadi S; Vijayabaskar MS; Peniket A; Bernard OA; Agresta S; Yen K; MacBeth K; Stein E; Vassiliou GS; Levine R; De Botton S; Thakurta A; Penard-Lacronique V; Vyas P
    Nat Med; 2018 Aug; 24(8):1167-1177. PubMed ID: 30013198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
    Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
    Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enasidenib for the treatment of acute myeloid leukemia.
    Dugan J; Pollyea D
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):755-760. PubMed ID: 29770715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
    Amatangelo MD; Quek L; Shih A; Stein EM; Roshal M; David MD; Marteyn B; Farnoud NR; de Botton S; Bernard OA; Wu B; Yen KE; Tallman MS; Papaemmanuil E; Penard-Lacronique V; Thakurta A; Vyas P; Levine RL
    Blood; 2017 Aug; 130(6):732-741. PubMed ID: 28588019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.